To understand whether the anti-NAFLD effects of MEG3 are mediated through targeting EZH2, we first measured EZH2 expression in hepatocytes expressing MEG3 or si-MEG3. Here, EZH2 is linked to metabolic dysfunction-associated steatotic liver disease.